RAMM Pharma Corp.
RAMM
CNSX
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -17.66% | -13.41% | -8.23% | -15.08% | -13.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -17.66% | -13.41% | -8.23% | -15.08% | -13.61% |
| Cost of Revenue | -28.58% | -42.08% | -40.93% | -45.13% | -1.32% |
| Gross Profit | 60.80% | 414.75% | 448.95% | 309.00% | -54.40% |
| SG&A Expenses | 14.79% | 23.33% | 45.35% | 42.50% | -17.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -12.26% | -16.19% | -18.12% | -16.96% | -- |
| Total Operating Expenses | -0.58% | -1.22% | 11.70% | 8.33% | -11.60% |
| Operating Income | -10.60% | -6.67% | -25.44% | -25.09% | 10.24% |
| Income Before Tax | -47.71% | -51.76% | -81.39% | -112.23% | 57.12% |
| Income Tax Expenses | 28.17% | 28.17% | -901.41% | -16.90% | 12.70% |
| Earnings from Continuing Operations | -47.68% | -51.73% | -80.26% | -112.07% | 57.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.68% | -51.73% | -80.26% | -112.07% | 57.09% |
| EBIT | -10.60% | -6.67% | -25.44% | -25.09% | 10.24% |
| EBITDA | -19.26% | -12.31% | -35.53% | -32.86% | 7.78% |
| EPS Basic | -47.45% | -51.63% | -80.62% | -113.47% | 56.05% |
| Normalized Basic EPS | 2.94% | -2.55% | -29.48% | -35.43% | -3.03% |
| EPS Diluted | -47.45% | -51.63% | -80.62% | -113.47% | 56.05% |
| Normalized Diluted EPS | 2.94% | -2.55% | -29.48% | -35.43% | -3.03% |
| Average Basic Shares Outstanding | 0.01% | -0.26% | -0.76% | -1.36% | -1.98% |
| Average Diluted Shares Outstanding | 0.01% | -0.26% | -0.76% | -1.36% | -1.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |